These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 22903535)
1. PPAR signaling pathway may be an important predictor of breast cancer response to neoadjuvant chemotherapy. Chen YZ; Xue JY; Chen CM; Yang BL; Xu QH; Wu F; Liu F; Ye X; Meng X; Liu GY; Shen ZZ; Shao ZM; Wu J Cancer Chemother Pharmacol; 2012 Nov; 70(5):637-44. PubMed ID: 22903535 [TBL] [Abstract][Full Text] [Related]
2. Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer. Yasojima H; Shimomura A; Naoi Y; Kishi K; Baba Y; Shimazu K; Nakayama T; Kim SJ; Tamaki Y; Noguchi S Eur J Cancer; 2011 Aug; 47(12):1779-88. PubMed ID: 21741827 [TBL] [Abstract][Full Text] [Related]
3. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. Hess KR; Anderson K; Symmans WF; Valero V; Ibrahim N; Mejia JA; Booser D; Theriault RL; Buzdar AU; Dempsey PJ; Rouzier R; Sneige N; Ross JS; Vidaurre T; Gómez HL; Hortobagyi GN; Pusztai L J Clin Oncol; 2006 Sep; 24(26):4236-44. PubMed ID: 16896004 [TBL] [Abstract][Full Text] [Related]
4. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures. Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249 [TBL] [Abstract][Full Text] [Related]
5. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer. Andre F; Mazouni C; Liedtke C; Kau SW; Frye D; Green M; Gonzalez-Angulo AM; Symmans WF; Hortobagyi GN; Pusztai L Breast Cancer Res Treat; 2008 Mar; 108(2):183-90. PubMed ID: 17468948 [TBL] [Abstract][Full Text] [Related]
6. Estrogen receptor-related genes as an important panel of predictors for breast cancer response to neoadjuvant chemotherapy. Chen Y; Chen C; Yang B; Xu Q; Wu F; Liu F; Ye X; Meng X; Mougin B; Liu G; Shen Z; Shao Z; Wu J Cancer Lett; 2011 Mar; 302(1):63-8. PubMed ID: 21220187 [TBL] [Abstract][Full Text] [Related]
7. Paclitaxel and carboplatin as neoadjuvant chemotherapy in patients with locally advanced breast cancer: A phase II Trial of the Hellenic Cooperative Oncology Group. Gogas H; Pectasides D; Kostopoulos I; Lianos E; Skarlos D; Papaxoinis G; Bobos M; Kalofonos HP; Petraki K; Pavlakis K; Bafaloukos D; Fountzilas G Clin Breast Cancer; 2010 Jun; 10(3):230-7. PubMed ID: 20497922 [TBL] [Abstract][Full Text] [Related]
8. Gene expression analysis of diagnostic biopsies predicts pathological response to neoadjuvant chemoradiotherapy of esophageal cancer. Maher SG; Gillham CM; Duggan SP; Smyth PC; Miller N; Muldoon C; O'Byrne KJ; Sheils OM; Hollywood D; Reynolds JV Ann Surg; 2009 Nov; 250(5):729-37. PubMed ID: 19801928 [TBL] [Abstract][Full Text] [Related]
9. Semaphorin-plexin signalling genes associated with human breast tumourigenesis. Gabrovska PN; Smith RA; Tiang T; Weinstein SR; Haupt LM; Griffiths LR Gene; 2011 Dec; 489(2):63-9. PubMed ID: 21925246 [TBL] [Abstract][Full Text] [Related]
10. Immediate gene expression changes after the first course of neoadjuvant chemotherapy in patients with primary breast cancer disease. Modlich O; Prisack HB; Munnes M; Audretsch W; Bojar H Clin Cancer Res; 2004 Oct; 10(19):6418-31. PubMed ID: 15475428 [TBL] [Abstract][Full Text] [Related]
11. [Clinical evaluation of effects from neoadjuvant chemotherapy with epirubicin plus paclitaxel in cases of locally advanced breast cancer--comparative study of treatment with 2 and 4 cycles]. Tong F; Yang D; Zhou B; Cao Y; Liu P; Liu H; Wang S; Qiao X; Zhang J Gan To Kagaku Ryoho; 2004 Feb; 31(2):205-8. PubMed ID: 14997752 [TBL] [Abstract][Full Text] [Related]
12. Changing the expression vector of multidrug resistance genes is related to neoadjuvant chemotherapy response. Litviakov NV; Cherdyntseva NV; Tsyganov MM; Denisov EV; Garbukov EY; Merzliakova MK; Volkomorov VV; Vtorushin SV; Zavyalova MV; Slonimskaya EM; Perelmuter VM Cancer Chemother Pharmacol; 2013 Jan; 71(1):153-63. PubMed ID: 23053273 [TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics. Lips EH; Mulder L; de Ronde JJ; Mandjes IA; Vincent A; Vrancken Peeters MT; Nederlof PM; Wesseling J; Rodenhuis S Breast Cancer Res Treat; 2012 Feb; 131(3):827-36. PubMed ID: 21472434 [TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant chemoradiation with paclitaxel/carboplatin for selected Stage III non-small-cell lung cancer: long-term results of a trimodality Phase II protocol. Hehr T; Friedel G; Steger V; Spengler W; Eschmann SM; Bamberg M; Budach W Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1376-81. PubMed ID: 19864078 [TBL] [Abstract][Full Text] [Related]
15. Prediction of pathologic complete response to sequential paclitaxel and 5-fluorouracil/epirubicin/cyclophosphamide therapy using a 70-gene classifier for breast cancers. Naoi Y; Kishi K; Tanei T; Tsunashima R; Tominaga N; Baba Y; Kim SJ; Taguchi T; Tamaki Y; Noguchi S Cancer; 2011 Aug; 117(16):3682-90. PubMed ID: 21305539 [TBL] [Abstract][Full Text] [Related]
16. Predicting response to docetaxel neoadjuvant chemotherapy for advanced breast cancers through genome-wide gene expression profiling. Zembutsu H; Suzuki Y; Sasaki A; Tsunoda T; Okazaki M; Yoshimoto M; Hasegawa T; Hirata K; Nakamura Y Int J Oncol; 2009 Feb; 34(2):361-70. PubMed ID: 19148470 [TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant chemotherapy for locally advanced breast cancer results in alterations in preoperative tumor marker status. Piper GL; Patel NA; Patel JA; Malay MB; Julian TB Am Surg; 2004 Dec; 70(12):1103-6. PubMed ID: 15663054 [TBL] [Abstract][Full Text] [Related]
18. DNA repair signature is associated with anthracycline response in triple negative breast cancer patients. Rodriguez AA; Makris A; Wu MF; Rimawi M; Froehlich A; Dave B; Hilsenbeck SG; Chamness GC; Lewis MT; Dobrolecki LE; Jain D; Sahoo S; Osborne CK; Chang JC Breast Cancer Res Treat; 2010 Aug; 123(1):189-96. PubMed ID: 20582464 [TBL] [Abstract][Full Text] [Related]
19. A phase II trial of a neoadjuvant platinum regimen for locally advanced breast cancer: pathologic response, long-term follow-up, and correlation with biomarkers. Yerushalmi R; Hayes MM; Gelmon KA; Chia S; Bajdik C; Norris B; Speers C; Hassell P; O'Reilly SE; Allan S; Shenkier TN Clin Breast Cancer; 2009 Aug; 9(3):166-72. PubMed ID: 19661040 [TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant chemotherapy in stage III breast cancer. Alassas M; Chu Q; Burton G; Ampil F; Mizell J; Li BD Am Surg; 2005 Jun; 71(6):487-92. PubMed ID: 16044927 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]